University of Utah-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of Utah - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013295
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of Utah (University of Utah) is a research university that offers various undergraduate and postgraduate programs. The university offers educational programs in various fields such as architecture and planning, engineering, fine arts, health, humanities, law, medicine, business, dentistry, mines and earth sciences, nursing, pharmacy, science, and others. It also offers support for teaching and research, cooperative education, and teaching hospital services to the university community. University of Utah undertakes research on animal subjects, radiation and laboratory safety, resource for genetic and epidemiologic research, and others. The university offers career services through its career exploration center. The University of Utah is headquartered in Salt Lake City, Utah, the US.

University of Utah – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
University of Utah, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
University of Utah, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
University of Utah, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
University of Utah, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
University of Utah, Medical Devices Deals, 2011 to YTD 2017 9
University of Utah, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
University of Utah, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
NanoCarrier Enters into Research Agreement with University of Utah 11
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 12
Zhuhai Hokai Medical Instruments Enters into LOI with University of Utah 14
BioRestorative Therapies Enters Into Research Agreement With University of Utah 15
Licensing Agreements 16
EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 16
Navigen Pharma Enters into Licensing Agreement with University of Utah 17
Lone Star Thiotherapies Receives Intellectual Property Rights from University of Utah 18
Omicia Enters Into Licensing Agreement With University of Utah Health Sciences 19
Kineta Enters Into Licensing Agreement With University of Utah Research Foundation 20
Biotime Amends Licensing Agreement With University of Utah 21
BioRestorative Therapies Enters Into Licensing Agreement With The University of Utah 22
Acquisition 23
OrthoCyte Completes Acquisition Of Glycosan BioSystems 23
University of Utah – Key Competitors 25
University of Utah – Key Employees 26
University of Utah – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Government and Public Interest 29
Nov 06, 2017: Huntsman Cancer Institute Study Identifies Enhanced Impact of Treatment for Hereditary Cancer Patients 29
Nov 01, 2017: University of Utah Receives $47.5 Million Gift from Craig H. Neilsen Foundation for New State-of-the-Art Rehabilitation Hospital 30
Oct 17, 2017: $24 Million NIH Grant Funds HIV Research at U of U Health-Led CHEETAH Center 31
Oct 10, 2017: National MS Society Commits Nearly $14 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever 32
Oct 06, 2017: FDA awards six grants for natural history studies in rare diseases 33
Oct 05, 2017: New Research on Sperm Stem Cells has Implications for Male Infertility and Cancer 34
Jul 06, 2017: NIH and Collaborators Identify the Genomic Cause for Carey-Fineman-Ziter Syndrome 35
Mar 13, 2017: University Of Utah Engineers Use CRISPR Technology To Prevent Tissue Damage And Resulting Chronic Pain 37
Jul 13, 2016: The Wistar Institute and Partners Receive Nearly $23 Million from NIH to Advance HIV Cure Research 38
Jul 06, 2016: University of Utah spin-off awarded grant to develop new antibiotics 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
University of Utah, Pharmaceuticals & Healthcare, Key Facts 2
University of Utah, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
University of Utah, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
University of Utah, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
University of Utah, Deals By Therapy Area, 2011 to YTD 2017 8
University of Utah, Medical Devices Deals, 2011 to YTD 2017 9
University of Utah, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
NanoCarrier Enters into Research Agreement with University of Utah 11
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 12
Zhuhai Hokai Medical Instruments Enters into LOI with University of Utah 14
BioRestorative Therapies Enters Into Research Agreement With University of Utah 15
EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 16
Navigen Pharma Enters into Licensing Agreement with University of Utah 17
Lone Star Thiotherapies Receives Intellectual Property Rights from University of Utah 18
Omicia Enters Into Licensing Agreement With University of Utah Health Sciences 19
Kineta Enters Into Licensing Agreement With University of Utah Research Foundation 20
Biotime Amends Licensing Agreement With University of Utah 21
BioRestorative Therapies Enters Into Licensing Agreement With The University of Utah 22
OrthoCyte Completes Acquisition Of Glycosan BioSystems 23
University of Utah, Key Competitors 25
University of Utah, Key Employees 26
University of Utah, Other Locations 27
University of Utah, Subsidiaries 27

★海外企業調査レポート[University of Utah-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dolphin Hotels plc:企業の戦略・SWOT・財務分析
    Dolphin Hotels plc - Strategy, SWOT and Corporate Finance Report Summary Dolphin Hotels plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hokka Hokka:企業の戦略・SWOT・財務分析
    Hokka Hokka - Strategy, SWOT and Corporate Finance Report Summary Hokka Hokka - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Caris Life Sciences Inc:企業の製品パイプライン分析
    Summary Caris Life Sciences Inc (Caris Life) is a biotechnology company. The company’s molecular scientific offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make personalized treatment decisions. Its ADAPT biotargeting system, is a plat …
  • Campine NV (CAMB):企業の財務・戦略的SWOT分析
    Campine NV (CAMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Smartac Group China Holdings Ltd (395):企業の財務・戦略的SWOT分析
    Smartac Group China Holdings Ltd (395) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Magnotta Winery Corporation:企業の戦略・SWOT・財務分析
    Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report Summary Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BelAZ:企業の戦略・SWOT・財務分析
    BelAZ - Strategy, SWOT and Corporate Finance Report Summary BelAZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Mega Corporation Ltd:企業の戦略・SWOT・財務分析
    Mega Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Mega Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Himatsingka Seide Ltd:企業の戦略・SWOT・財務分析
    Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report Summary Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • DiaSorin SpA (DIA):医療機器:M&Aディール及び事業提携情報
    Summary DiaSorin S.p.A. (DiaSorin) is a medical diagnostics company that develops, manufactures and markets in vitro diagnostics reagent kits and systems. The company develops reagent kits based on Radioimmunometry (RIA), Enzyme Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA) techni …
  • Latvenergo AS:企業の戦略的SWOT分析
    Latvenergo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • CullenFrost Bankers Inc (CFR):企業の財務・戦略的SWOT分析
    CullenFrost Bankers Inc (CFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • MiMedx Group Inc – Product Pipeline Analysis, 2018 Uate
    Summary MiMedx Group Inc (MiMedx) is a biopharmaceutical company that develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary pur …
  • Emera (Caribbean) Inc.:発電所・企業SWOT分析
    Emera (Caribbean) Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • Esab Holdings Ltd:企業の戦略・SWOT・財務分析
    Esab Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Esab Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sotheby’s (BID):企業の財務・戦略的SWOT分析
    Sotheby's (BID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PPL Corp:企業の発電所・SWOT分析2018
    PPL Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executive …
  • Timberwest Forest Corporation:企業の戦略・SWOT・財務分析
    Timberwest Forest Corporation - Strategy, SWOT and Corporate Finance Report Summary Timberwest Forest Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆